Device Trials Go Unpublished

Just half of the clinical studies used to gain premarket approval for cardiac devices ever make it into the scientific literature.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, BRUCEBLAUSThe US Food and Drug Administration (FDA) makes available summaries of the clinical studies behind medical device approvals. But as researchers reported in The BMJ this month (June 10), these “are not easy to access,” and they found just half of the trials ultimately get published in the literature where clinicians might have an easier time reading them.

“This is important, as the new European Clinical Trials Regulation (which aims to improve clinical trials transparency) does not apply to clinical trials on medical devices, and previous research found that the FDA approves many of these devices on the basis of a single trial,” according to a post on the All Trials website, part of an initiative to get human studies registered and reported.

To conduct the latest analysis, Rita Redberg of the University of California, San Francisco, and colleagues collected documents from the FDA about 106 cardiovascular devices that received premarket approval between 2000 and 2010. Of the corresponding studies on these products, 49 percent were published in peer-reviewed journals by 2013.

“Even when trials are published, the study population, primary endpoints, and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies